A Long Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

• Status: Completed
• Trial end date: 2020-01-24
• Target enrollment: 0
• Participant gender: All

Summary

To assess the safety of S5G4T-1 when applied once daily for 24 to 48 weeks in patients with papulopustular rosacea

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sol-Gel Technologies, Ltd.

Criteria

Inclusion Criteria:

1. Patient must sign an Institutional Review Board (IRB) approved written informed consent for the extension study.

2. Complete 12 weeks of Phase 3.

Exclusion Criteria:

-